The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab as 1L treatment of BRAF V600E-mutant mCRC
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, provides an overview of the Phase II FIRE-4.5 study (NCT04034459), a randomized trial to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line (1L) treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
